Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Griseofulvin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cosette Pharmaceuticals Announces the Launch of Griseofulvin Oral Suspension, 125 mg/5 mL.
Details : Griseofulvin microsize contains griseofulvin microsize for oral administration. The active ingredient, griseofulvin, is a fungistatic antibiotic, derived from a species of Penicillium.
Brand Name : Griseofulvin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 06, 2022
Lead Product(s) : Griseofulvin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?